Payment overview · 2025
General Payments
$4,264.60
164 reported records · 26 companies
Healthcare provider profile · identity verified
Marwan Obid, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · PANAMA CITY, FL · NPI 1518945625
Verified facts
What the public records show
CMS Open Payments records show Marwan Obid, M.D received $4,264.60 in general payments during 2025 across 164 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Paxlovid, Tezspire, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tezspire by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $759.47 | 17.8% | 23 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $463.08 | 10.9% | 16 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $427.05 | 10.0% | 11 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $358.17 | 8.4% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $342.29 | 8.0% | 21 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $297.08 | 7.0% | 10 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $275.88 | 6.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $241.95 | 5.7% | 9 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $147.36 | 3.5% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $143.50 | 3.4% | 14 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $106.52 | 2.5% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $99.99 | 2.3% | 1 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $93.96 | 2.2% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $69.30 | 1.6% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $67.81 | 1.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.72 | 1.4% | 3 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $54.20 | 1.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $52.62 | 1.2% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $37.23 | 0.9% | 4 | 2025 |
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $33.89 | 0.8% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $28.67 | 0.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.26 | 0.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $23.52 | 0.6% | 1 | 2025 |
| ADMA BioManufacturing LLC | Unresolved — no canonical attribution shown | $23.50 | 0.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.01 | 0.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.57 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,107.11 | 161 |
| Education | $133.99 | 2 |
| Consulting Fee | $23.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $990.12 | 28 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $458.48 | 18 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $365.52 | 10 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $358.17 | 13 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $275.88 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $241.95 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $222.30 | 13 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $171.25 | 5 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $165.67 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $144.63 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $131.65 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $129.89 | 5 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $119.99 | 8 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $93.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $93.05 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $91.57 | 3 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $69.30 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $67.81 | 3 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $59.95 | 3 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $52.62 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | Octapharma USA, Inc., PFIZER INC. | $50.04 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $37.69 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $37.23 | 4 | 2025 |
Source payment records
|
|||||
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $28.67 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.22 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.22 | 3 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $17.47 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $2.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 29 | exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
175 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 330 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 295 | 86 |
| Omeprazole | Omeprazole | 277 | 80 |
| Furosemide | Furosemide | 252 | 74 |
| Alprazolam | Alprazolam | 242 | 55 |
| Montelukast Sodium | Montelukast Sodium | 232 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 63 |
| Losartan Potassium | Losartan Potassium | 222 | 55 |
| Carvedilol | Carvedilol | 208 | 66 |
| Lisinopril | Lisinopril | 182 | 48 |
| Potassium Chloride | Potassium Chloride | 182 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 175 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 47 |
| Gabapentin | Gabapentin | 159 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 57 |
| Azithromycin | Azithromycin | 153 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 34 |
| Levofloxacin | Levofloxacin | 147 | 79 |
| Sertraline Hcl | Sertraline Hcl | 141 | 39 |
| Prednisone | Prednisone | 132 | 46 |
| Metformin Hcl | Metformin Hcl | 131 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 102 | 57 |
| Methylprednisolone | Methylprednisolone | 102 | 64 |
| Ezetimibe | Ezetimibe | 97 | 28 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 92 | 16 |
| Meloxicam | Meloxicam | 88 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 32 |
| Cephalexin | Cephalexin | 76 | 49 |
| Ozempic | Semaglutide | 76 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 75 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 66 | 26 |
| Allopurinol | Allopurinol | 63 | 19 |
| Simvastatin | Simvastatin | 61 | 19 |
| Eliquis | Apixaban | 60 | 18 |
| Januvia | Sitagliptin Phosphate | 58 | 12 |
| Buspirone Hcl | Buspirone Hcl | 57 | 16 |
| Jardiance | Empagliflozin | 55 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 15 |
| Famotidine | Famotidine | 52 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 37 |
| Donepezil Hcl | Donepezil Hcl | 48 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 15 |
| Fluconazole | Fluconazole | 48 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Glipizide | Glipizide | 46 | 14 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 43 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | 13 |
| Amoxicillin | Amoxicillin | 42 | 31 |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 12 |
| Meclizine Hcl | Meclizine Hcl | 35 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 13 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 13 |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 11 |
| Eszopiclone | Eszopiclone | 30 | 13 |
| Finasteride | Finasteride | 30 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Dupixent Syringe | Dupilumab | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 18 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Nystatin | Nystatin | 22 | 11 |
| Topiramate | Topiramate | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Sulindac | Sulindac | 17 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Aralast Np | Alpha-1-Proteinase Inhibitor | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | 11 |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tezspire | Tezepelumab-Ekko | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,264.60 · 164 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Andembry, Arikayce, BREZTRI, Brinsupri, CUTAQUIG, DUPIXENT, FARXIGA, FASENRA, Hizentra, INSPIRE, JARDIANCE, JASCAYD, LUMRYZ, Leqembi, NEFFY, NUCALA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, ORLADEYO, OTEZLA, Ohtuvayre, Ozempic, PANZYGA, PAXLOVID, Prolastin-C Liquid, REPATHA, RUCONEST, Rhapsido, Rybelsus, SMARTVEST, TEZSPIRE, TRELEGY ELLIPTA, VOQUEZNA, XYOSTED, Xembify, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error